Investor Relations

VBL Therapeutics to Report First Quarter 2018 Financial Results on May 17

May 01, 2018

TEL AVIV, Israel, May 01, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, May 17 at 8:30am Eastern Time to report first quarter ended March 31, 2018 financial results.

Thursday, May 17th @ 8:30am Eastern Time
US Domestic:            877-222-6394
International:             1-703-925-2702
Conference ID:          9993639
Webcast:                    https://edge.media-server.com/m6/p/zja7xger

Replays, Available through May 31, 2018
US Domestic:            855-859-2056
International:             1-404-537-3406
Conference ID:          9993639

About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 trial for platinum-resistant ovarian cancer.

INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979

Primary Logo